Author:
Viedma-Martínez M.,Gallo-Pineda G.,Jiménez-Gallo D.
Reference11 articles.
1. Criterios para valorar la administración de las nuevas alternativas terapéuticas antivirales frente a la infección por SARS-CoV-2. Agencia Española de Medicamentos y Productos Sanitarios; 2022. Available from: https://www.aemps.gob.es/medicamentos-de-uso-humano/acceso-a-medicamentos-en-situaciones-especiales/criterios-para-valorar-la-administracion-de-las-nuevas-alternativas-terapeuticas-antivirales-frente-a-la-infeccion-por-sars-cov-2/ [Cited 2022 Jun 5].
2. COVID-19 and immunomodulator/immunosuppressant use in dermatology;Price;J Am Acad Dermatol,2020
3. COVID-19 in immunocompromised hosts: what we know so far;Fung;Clin Infect Dis,2021
4. Early treatment for covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab;Gupta;N Engl J Med,2021
5. Severe acute respiratory syndrome-coronavirus-2 infection and patients with lung cancer: the potential role of interleukin-17 target therapy;Cafarotti;J Thorac Oncol,2020